Capricor Therap (CAPR) Stock Price, Quote & News

Company Profile

Capricor Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States. Its lead product candidate is the Deramiocel, an allogeneic cardiosphere-derived cells, which is in phase 3 clinical trial for the treatment of DMD. The company also develops Exosome protein-based vaccine, which is in preclinical trial t...

Industry: Biotechnology

Sector: Healthcare

Phone: 858 727 1755

Website: www.capricor.com

Address:

10865 Road to the Cure, Suite 150, San Diego, United States

Kingcrab26 Feb. 4 at 5:12 AM

$ATOS $CADL $CAPR $PYPL $SLS

0 · Reply

hegdaom Feb. 4 at 4:34 AM

$CAPR

0 · Reply

LongLongStock Feb. 4 at 4:19 AM

i hold my shares because i can justify 200 dollars valuation when they get approved and commercialization ; and i believe they got a winning product. $CAPR Sleeping well with 22,500 shares

2 · Reply

spaceodyssey2001 Feb. 4 at 4:17 AM

$CAPR Elijah Stacy from a recent X post "Very proud of my younger brother, Kai, for using his voice and talking about his experience being on Deramiocel. He felt much more energized, stronger, and even could tell when his next dosing session was coming up. Kai is very smart and wants to accomplish a lot in his life. He’s always learning something new or wanting to debate me on some metaphysical issue. I’ve already lost a brother, Max, who had DMD, so I really don’t want to lose another or have my parents experience another loss of their children. My hope for both Kai and I is that we can be on Deramiocel soon via an immediate FDA approval and live a longer lifespan!"

1 · Reply

hegdaom Feb. 4 at 4:05 AM

$CAPR 👏

0 · Reply

hegdaom Feb. 4 at 3:31 AM

$CAPR $CADL

0 · Reply

hegdaom Feb. 4 at 3:30 AM

$CAPR

0 · Reply

hegdaom Feb. 4 at 3:25 AM

$CAPR

0 · Reply

hegdaom Feb. 4 at 3:24 AM

$CAPR

0 · Reply

spaceodyssey2001 Feb. 4 at 2:01 AM

$MSCLF Recent post from Elijah Stacy, who has Duchenne muscular dystrophy, has worked at Capricor $CAPR and Satellos and is the founder of Destroy Duchenne. "Today, I added 100,000+ shares of Satellos $MSCL to my current position! I think this could be a truly revolutionary drug. Let’s go change the world. Exciting times ahead for DMD & regenerative medicine!"

1 · Reply

Capricor Therapeutics, Inc. (CAPR) Discusses HOPE-3 Phase III Trial Results and Regulatory Path for Duchenne Muscular Dystrophy Therapy Transcript

Dec 7, 2025, 8:21 AM EST - 2 months ago

Capricor: Maintaining 'Hold' Rating On Randomized Phase 3 HOPE-3 Trial Win With Deramiocel

Dec 6, 2025, 1:18 AM EST - 2 months ago

Capricor Therapeutics, Inc. (CAPR) Discusses HOPE-3 Phase III Top Line Data for Deramiocel in Duchenne Muscular Dystrophy Transcript

Dec 4, 2025, 4:01 PM EST - 2 months ago

Capricor Therapeutics Announces Proposed Public Offering of Common Stock

Dec 3, 2025, 2:21 PM EST - 2 months ago

Capricor Stock Soars, Shkreli Is Short: Here's What Pharma Bro Had To Say

Dec 3, 2025, 9:23 AM EST - 2 months ago

Capricor Therapeutics Duchenne Treatment Shows Strong Heart And Muscle Results In Trial

Dec 3, 2025, 7:44 AM EST - 2 months ago

Capricor's muscle disorder cell therapy succeeds in late-stage study

Nov 24, 2025, 1:49 PM EST - 2 months ago

Martin Shkreli Takes Aim At Capricor — Stock Sinks

Nov 10, 2025, 11:21 PM EST - 3 months ago

Capricor Therapeutics, Inc. (CAPR) Q3 2025 Earnings Call Transcript

Nov 3, 2025, 9:15 AM EST - 3 months ago

Capricor Therapeutics Publishes Peer-Reviewed Study in Biomedicines Describing the Mechanism of Action and Potency Assay for its Investigational Cell Therapy, Deramiocel

Oct 31, 2025, 9:15 AM EDT - 3 months ago

Capricor Therapeutics to Present Third Quarter 2025 Financial Results and Recent Corporate Update on November 10

Oct 3, 2025, 10:45 AM EDT - 4 months ago

Capricor Therapeutics, Inc. Long-Term Shareholder Announcement: Johnson Fistel Encourages Investors to Reach Out For More Information About Continuing Investigation

Sep 29, 2025, 3:51 PM EDT - 4 months ago

Capricor: Post-CRL Path To DMD Cardiomyopathy Approval In 2026

Sep 29, 2025, 9:08 AM EDT - 4 months ago

Capricor Therapeutics: A Buy Ahead Of Phase 3 Topline And Clarified Regulatory Pathway

Sep 25, 2025, 11:07 AM EDT - 4 months ago

Capricor Therapeutics, Inc. - Special Call

Sep 25, 2025, 7:15 AM EDT - 4 months ago

Capricor Therapeutics Provides Regulatory Update on Deramiocel Program for Duchenne Muscular Dystrophy Following Type A Meeting

Sep 13, 2025, 11:35 AM EDT - 5 months ago

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Capricor Therapeutics

Sep 9, 2025, 9:20 AM EDT - 5 months ago

Capricor Therapeutics Responds to FDA Posting of Complete Response Letter (CRL) for Deramiocel

Aug 28, 2025, 7:05 PM EDT - 5 months ago

SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Capricor Therapeutics

Aug 22, 2025, 10:20 AM EDT - 5 months ago

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Capricor Therapeutics

Aug 18, 2025, 11:35 AM EDT - 6 months ago

Capricor Therapeutics, Inc. (CAPR) Q2 2025 Earnings Conference Call Transcript

Aug 8, 2025, 8:30 AM EDT - 6 months ago

Capricor Therapeutics Announces Type A Meeting Scheduled with U.S. FDA

Aug 6, 2025, 9:00 AM EDT - 6 months ago

Capricor Therapeutics to Present Second Quarter 2025 Financial Results and Recent Corporate Update on August 13

Jul 31, 2025, 8:45 AM EDT - 6 months ago

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of September 15, 2025 in Capricor Therapeutics, Inc. Lawsuit - CAPR

Jul 30, 2025, 4:27 PM EDT - 6 months ago

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of September 15, 2025 in Capricor Therapeutics, Inc. Lawsuit – CAPR

Jul 30, 2025, 11:07 AM EDT - 6 months ago

What's Going On With Sarepta, Capricor And Other Gene Therapy Stocks On Wednesday?

SRPT CABA NGNE NTLA QURE RCKT

Jul 17, 2025, 4:46 PM EDT - 7 months ago

BREAKING: Capricor Therapeutics Sued For Securities Fraud; Investors Should Contact Block & Leviton to Potentially Recover Losses

Jul 16, 2025, 7:55 PM EDT - 7 months ago

Bragar Eagel & Squire, P.C. is Investigating Capricor Therapeutics, Inc. on Behalf of Capricor Stockholders and Encourages Investors to Contact the Firm

Jul 14, 2025, 4:14 PM EDT - 7 months ago

Wolf Popper LLP Announces Investigation on Behalf of Capricor Therapeutics, Inc. Investors

Jul 14, 2025, 7:43 AM EDT - 7 months ago

Capricor Therapeutics: Buying Opportunity Following FDA's Complete Response Letter

Kingcrab26 Feb. 4 at 5:12 AM

$ATOS $CADL $CAPR $PYPL $SLS

0 · Reply

hegdaom Feb. 4 at 4:34 AM

$CAPR

0 · Reply

LongLongStock Feb. 4 at 4:19 AM

i hold my shares because i can justify 200 dollars valuation when they get approved and commercialization ; and i believe they got a winning product. $CAPR Sleeping well with 22,500 shares

2 · Reply

spaceodyssey2001 Feb. 4 at 4:17 AM

1 · Reply

hegdaom Feb. 4 at 4:05 AM

$CAPR 👏

0 · Reply

hegdaom Feb. 4 at 3:31 AM

$CAPR $CADL

0 · Reply

hegdaom Feb. 4 at 3:30 AM

$CAPR

0 · Reply

hegdaom Feb. 4 at 3:25 AM

$CAPR

0 · Reply

hegdaom Feb. 4 at 3:24 AM

$CAPR

0 · Reply

spaceodyssey2001 Feb. 4 at 2:01 AM

1 · Reply

francoa1 Feb. 4 at 1:41 AM

$CAPR PRV program reauthorized for 5 years. One less silly excuse to undercut the value here.

0 · Reply

Evagaminska Feb. 4 at 12:56 AM

$NVO What actually is happening with biotech companies and big pharma? We aren’t getting timely communication from clowns at FDA, delay approval like for rare diseases $SRPT $CAPR Not much MNA It’s seem innovation is dead and now with Makary,Prasad & Oz the whole medical&health insurance system is collapsing?

1 · Reply

NoSwagger Feb. 4 at 12:50 AM

$CAPR more buying AH?

0 · Reply

Macme Feb. 4 at 12:25 AM

$CAPR We are enjoying the curving.

0 · Reply

dnfrs Feb. 4 at 12:15 AM

$CAPR When submission is complete there are catalysts galore in coming months. 1. Phase 3 data article published in leading medical journal 2. FDA announcing new PDUFA date 3. Deramiocel FDA approval 4. Deramiocel European + ROW PARTNERSHIP (with NS or Big Pharma ?) 5. More NS milestones for Deramiocel in Japan 6. Becker will advance (approval or trial) 7. StealthX Covid vaccine results (NIAID funded) 8. StealthX Big Pharma and/or more NIAID PARTNERSHIP(s) 9. Deramiocel US earnings in 2026 10. Increased number of Analysts 11. Quarterly Report updates 12. Increased Share Price Targets by Analysts 13. TY1 from Marban Labs enters clinic 14. Increased chatter about buyout ! Capricor is cash rich with some $300 million in cash; an $80 million NS milestone upon Deramiocel US approval and a PRV worth as much as $200 million + new partnership upfronts and milestones !

4 · Reply

Steadyrockin Feb. 3 at 11:48 PM

$CAPR A little bit of after-market activity.

0 · Reply

Stringbag Feb. 3 at 11:39 PM

$CAPR holding 5k shares for $200 aka until it’s worth $1M

3 · Reply

golf4life28 Feb. 3 at 11:37 PM

$CAPR Catalyst, Catalyst! Pre-Market & When (WIN) Coming soon?!?! Let’s Gooooo! extremely

1 · Reply

quickaspeter Feb. 3 at 10:18 PM

$CAPR I like your thinking.. thanks for sharing!

1 · Reply

Svenson1984 Feb. 3 at 10:14 PM

$CAPR back to offering price…. The delay of the submission definitely had its impact

1 · Reply

haha1978 Feb. 3 at 10:14 PM

$CAPR macd curling up next few days should return and test 27 and then 30 eventually for the start of the next wave up.

0 · Reply

Machman1 Feb. 3 at 10:13 PM

$CAPR if vaccine data is good. I expect us to become a buyout target

5 · Reply

Market Cap	1.00B
Revenue (ttm)	22.27M
Net Income (ttm)	-40.47M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	36.38
Profit Margin	-181.72%
Debt to Equity Ratio	0.00

Volume	1,241,400
Avg Vol	3,101,328
Day's Range	N/A - N/A
Shares Out	45.72M
Stochastic %K	99%
Beta	0.22
Analysts	Strong Sell
Price Target	$50.80